Virtual Library
Start Your Search
M. Lai
Author of
-
+
P1.12 - Poster Session 1 - NSCLC Early Stage (ID 203)
- Event: WCLC 2013
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 1
- Moderators:
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.12-005 - Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer (ID 1235)
09:30 - 09:30 | Author(s): M. Lai
- Abstract
Background
Asian ethnicity is associated with distinct molecular etiology, treatment response, and survival among patients with non-small cell lung cancer (NSCLC). This study examines the survival impact of platinum-based adjuvant chemotherapy for Asian patients with stage I-IIIA NSCLC.Methods
This study recruited patients ³ 18 years old with histologically proven stage IA-IIIA NSCLC registered in the Taiwan Cancer Registry Database between January 2004 and December 2007. Platinum-containing adjuvant chemotherapy should be started within 90 days of the primary surgery. Kaplan-Meier survival curves, log-rank tests, and the Cox proportional hazards regression model were used to assess the influence of various risk factors on survival time.Results
This study included 2,231 patients with stage IA to IIIA NSCLC who underwent primary surgery with a clear surgical margin. The percentages of all causes of death were significantly lower for the chemotherapy group in stage II and stage IIIA patients. Multivariate analysis identified platinum-based adjuvant chemotherapy as an independent prognostic factor for the overall survival of stage II (HR 0.61, 95% CI 0.39-0.94, p = 0.024) and IIIA (HR 0.71, 95% CI 0.52-0.96, p = 0.029) patients. Among these patients, those who received adjuvant chemotherapy demonstrated superior overall survival in both genders and in the subgroups of patients aged ³ 70 years and those with adenocarcinoma.Conclusion
Platinum-based adjuvant chemotherapy should be considered in the treatment plan for Asian patients with resected stage II and stage IIIA NSCLC.
-
+
P3.13 - Poster Session 3 - SCLC (ID 202)
- Event: WCLC 2013
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 1
- Moderators:
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.13-003 - Survival of patients with small cell lung carcinoma in Taiwan (ID 1252)
09:30 - 09:30 | Author(s): M. Lai
- Abstract
Background
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer. The prognosis for SCLC patients remains unsatisfactory, despite advances in chemotherapy. In this study, we sought to clarify the prognosis and treatment patterns of patients with SCLC.Methods
A cohort comprising all patients diagnosed with SCLC between Jan. 2004 and Dec. 2006 was assembled from the Taiwan Cancer Database. Patients were followed up until December 31, 2009 to determine overall survival. Patient survival was estimated using the Kaplan-Meier method, and Cox’s proportional hazard model was used to determine the relationship between prognostic factors and median survival time.Results
Among the 1684 patients diagnosed with SCLC, 1215 (72%) were diagnosed with extensive stage, and 469 (28%) with limited stage. Most of the patients were male (90%). The median survival time of patients with limited-stage (LS) and extensive-stage (ES) SCLC was 10.3 months and 5.6 months, respectively. For LS patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy resulted in better survival than best supportive care (HR: 0.20, p<0.001; HR: 0.61, p<0.001; HR: 0.37, p<0.001 respectively). For ES patients, male gender was significantly associated with poor prognosis (HR:1.45, p<0.001) and chemotherapy was shown to improve overall survival more effectively than best supportive care (HR: 0.37, p<0.001).Conclusion
For LS SCLC patients, surgery, chemotherapy, and combined chemotherapy and radiotherapy improved survival compared to best supportive care. ES SCLC patients benefited more from chemotherapy treatment than best supportive care.
